Higher efficacy Aside from pricing competition and label expansion, greater efficacy in HbA1c reduction and/or weight loss, reduced side-effects and increased patient convenience (eg an oral tablet rather than a subcutaneous injection) will also contribute to the success of new GLP-1s and associated weight loss medication
GLP-1 physiology informs the pharmacotherapy of obesity
The story of GLP-1 medicines begins with the Gila monster ( Heloderma suspectum ), a venomous lizard native to the southwestern United States and northwestern Mexico
Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, et al
GLP-1 agonists include (not all are available in Australia): semaglutide (brand names Ozempic, Wegovy, Rybelsus), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), exenatide (Byetta, Bydureon) and lixisenatide (Lyxumia, Adlyxin)
Furthermore, we expanded the search for specific additions to the terms back pain, chest pain, cough, syncope, and urinary tract infection by also including urinary tract infections with specific bacterial etiology, noncardiac chest pain, productive cough, and unconsciousness in addition to the narrower search terms used by Elashoff et al
